Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SNDX – Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.
SNDX
$17.18
Name : Syndax Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,493,196,928.00
EPSttm : -3.6
finviz dynamic chart for SNDX
Syndax Pharmaceuticals, Inc.
$17.18
3.37%
$0.56

Float Short %

30.13

Margin Of Safety %

Put/Call OI Ratio

0.42

EPS Next Q Diff

0.16

EPS Last/This Y

0.68

EPS This/Next Y

1.42

Price

17.18

Target Price

38.31

Analyst Recom

1.07

Performance Q

11.59

Relative Volume

1.16

Beta

0.46

Ticker: SNDX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20SNDX15.570.350.1834756
2025-10-21SNDX15.190.350.4335821
2025-10-22SNDX15.120.360.0937533
2025-10-23SNDX14.680.360.1137822
2025-10-24SNDX13.50.360.3438848
2025-10-27SNDX13.10.370.2348225
2025-10-28SNDX13.510.380.3049102
2025-10-29SNDX13.220.380.1250314
2025-10-30SNDX13.40.390.1350517
2025-10-31SNDX13.70.400.4749844
2025-11-03SNDX12.850.410.6851816
2025-11-04SNDX15.360.420.7152884
2025-11-05SNDX15.10.470.2453430
2025-11-06SNDX14.680.430.0752437
2025-11-07SNDX15.040.440.6052249
2025-11-10SNDX15.710.450.0952608
2025-11-11SNDX17.720.460.1652080
2025-11-12SNDX16.80.450.3552284
2025-11-13SNDX16.660.450.1352309
2025-11-14SNDX16.630.420.1455006
2025-11-17SNDX17.210.420.6855092
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20SNDX15.5727.5171.3-3.12
2025-10-21SNDX15.2027.5193.6-3.12
2025-10-22SNDX15.1127.5190.2-3.12
2025-10-23SNDX14.6727.5194.8-3.12
2025-10-24SNDX13.5127.5205.0-3.12
2025-10-27SNDX13.1027.5195.8-3.12
2025-10-28SNDX13.5127.5182.6-3.11
2025-10-29SNDX13.2127.5193.8-3.11
2025-10-30SNDX13.3927.5186.5-3.11
2025-10-31SNDX13.7027.5193.2-3.10
2025-11-03SNDX13.7727.5196.7-3.10
2025-11-04SNDX15.3527.5175.8-3.10
2025-11-05SNDX15.0927.5200.9-3.10
2025-11-06SNDX14.6850.5170.9-3.04
2025-11-07SNDX15.0450.5211.7-3.04
2025-11-10SNDX15.7250.5209.6-3.04
2025-11-11SNDX17.7352.0201.2-3.02
2025-11-12SNDX16.8153.5219.3-3.02
2025-11-13SNDX16.6553.5215.1-2.99
2025-11-14SNDX16.6250.7214.5-3.04
2025-11-17SNDX17.1850.7211.0-3.04
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20SNDX-6.572.4827.37
2025-10-21SNDX-6.572.4827.37
2025-10-22SNDX-6.572.4827.37
2025-10-23SNDX-6.572.4827.37
2025-10-24SNDX-6.572.4827.37
2025-10-27SNDX-6.570.6626.43
2025-10-28SNDX-6.570.6626.43
2025-10-29SNDX-6.570.6626.43
2025-10-30SNDX-6.570.6626.43
2025-10-31SNDX-6.570.6626.43
2025-11-03SNDX-6.570.6626.43
2025-11-04SNDX-6.570.6626.43
2025-11-05SNDX-6.570.6626.43
2025-11-06SNDX-6.520.6626.19
2025-11-07SNDX-6.520.6626.19
2025-11-10SNDX-6.524.5726.19
2025-11-11SNDX-6.524.5726.19
2025-11-12SNDX-6.524.5730.14
2025-11-13SNDX-6.524.5730.14
2025-11-14SNDX-6.524.5730.13
2025-11-17SNDX-6.585.2330.13
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.7

Avg. EPS Est. Current Quarter

-0.54

Avg. EPS Est. Next Quarter

-0.54

Insider Transactions

-6.58

Institutional Transactions

5.23

Beta

0.46

Average Sales Estimate Current Quarter

67

Average Sales Estimate Next Quarter

75

Fair Value

Quality Score

41

Growth Score

47

Sentiment Score

77

Actual DrawDown %

42.5

Max Drawdown 5-Year %

-69.9

Target Price

38.31

P/E

Forward P/E

PEG

P/S

13.39

P/B

12.93

P/Free Cash Flow

EPS

-3.62

Average EPS Est. Cur. Y​

-3.04

EPS Next Y. (Est.)

-1.62

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-279.31

Relative Volume

1.16

Return on Equity vs Sector %

-296.9

Return on Equity vs Industry %

-281.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

211
Syndax Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 270
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today
news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance
stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market
stock prices SNDX premarket after hours
ticker SNDX fair value insiders trading